Reta 40mg
Retatrutide · 40mg vial
Research use only · Not for human or veterinary consumption · Not for self-administration
Retatrutide is a single investigational molecule designed to activate three receptors: GIP, GLP-1 and glucagon. These pathways influence appetite, glucose handling and energy balance.
Pricing · per unit
Mix & match any vials — 2–4 −10%, 5+ −15%In transit · ETA 20 Nov
How it works
The two incretin signals act on nutrient and appetite pathways, while glucagon adds a separate metabolic signal. It is being studied as a once-weekly treatment in controlled clinical trials.
Research context
Phase 2 and phase 3 studies are evaluating obesity and metabolic disease. Lilly states that retatrutide remains investigational; results from a trial do not establish a protocol for unapproved vials.
Vial contents & handling
- 40mg retatrutide
- Single lyophilised vial
Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — ask us on WhatsApp ↗
Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.
Research reference dosage
40mg vial · 3ml water · 13.33mg/ml| Level | Amount | U100 units | Frequency |
|---|---|---|---|
| Beginner | 2mg | 15 units | Once weekly or split 2× weekly · any time |
| Intermediate | 4–6mg | 30–45 units | Once weekly or split 2× weekly · any time |
| Advanced | 8–12mg | 60–90 units | Once weekly or split 2× weekly · any time |
Fixed 3ml · U100 device (1 unit = 0.01ml). For split weekly schedules, use half the listed full-amount units per administration. Research reference only—not human-use guidance.